Tonix Pharmaceuticals Holding Corp. (TNXP) News
Follow Tonix Pharmaceuticals Holding Corp. (TNXP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Tonix Pharmaceuticals CEO Acquires $20,275 in Common Shares
Tonix Pharmaceuticals CEO Seth Lederman acquired $20,275 in common shares.
EQUITY | Nov 12, 2026, 01:03 PM UTC
M
Tonix Pharmaceuticals Q3 Revenue Jumps on TONMYA Sales
EQUITY | Nov 09, 2026, 12:23 PM UTC
M
Tonix Pharmaceuticals to Report Third-Quarter Financial Results
EQUITY | Oct 26, 2026, 11:09 AM UTC
M
Tonix Pharmaceuticals signs second major Medicare managed payer deal for Tonmya
Tonix Pharmaceuticals Holding Corp. said it has reached a second major managed Medicare payer agreement for its Tonmya®.
EQUITY | Sep 22, 2026, 11:02 AM UTC
L
TNXP - Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
TNXP - Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
NEWS | Sep 22, 2026, 11:00 AM UTC
L
Tonix promotes Thomas Englese to chief commercial officer
Tonix Pharmaceuticals promoted Thomas Englese to chief commercial officer, effective immediately, to lead and expand commercial activities for TONMYA and other marketed products.
REGULATION | Sep 08, 2026, 11:13 AM UTC
L
Tonix names Thomas Englese as Chief Commercial Officer
Tonix Pharmaceuticals promoted Thomas Englese, MBA, to Chief Commercial Officer, after leading the company’s commercial organization since 2024. His role included go-to-market strategy and the U.S. launch of TONMYA® with
EQUITY | Sep 08, 2026, 11:08 AM UTC
L
Tonix Pharmaceuticals promotes Thomas Englese to Chief Commercial Officer
Tonix Pharmaceuticals promoted Thomas Englese, MBA, to Chief Commercial Officer.
EQUITY | Sep 08, 2026, 11:00 AM UTC
L
Tonix Pharmaceuticals to participate in Cantor 2026 Global Healthcare conference
Tonix Pharmaceuticals’ management team will participate in Cantor’s 2026 Global Healthcare Conference via a fireside chat and 1x1 meetings.
EQUITY | Sep 02, 2026, 11:07 AM UTC
L
TNXP - Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
TNXP - Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference
EQUITY | Sep 02, 2026, 11:00 AM UTC
L
TNXP - Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human
TNXP - Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
REGULATION | Aug 03, 2026, 11:00 AM UTC
M
TNXP: Raymond James Initiates
Raymond James analyst initiates coverage on Tonix Pharmaceuticals with a Strong Buy rating and a price target of $26
EQUITY | Jun 25, 2026, 12:44 PM UTC
H
MPLT, TNXP: Strong Buy
Benchmark initiates MPLT and TNXP with a strong buy rating
EQUITY | Jun 25, 2026, 10:54 AM UTC
M
TNXP: Raymond James Initiates
Raymond James initiates coverage on Tonix Pharmaceuticals with a Strong Buy rating and $26 price target
EQUITY | Jun 25, 2026, 10:02 AM UTC